Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057212 · ClinicalTrials.gov registry record · Phase 2
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Providence Health & Services.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01057212 is a Phase 2 study that was terminated before completion, run by Providence Health & Services. The registered enrollment target is 6 participants.
The verdict
NCT01057212, a Phase 2 study, was terminated before completion, sponsored by Providence Health & Services.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a non-randomized, open-label, single arm phase II trial of the combination of bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC progressive after first or second-line therapy. The main objective is to evaluate the progression-free survival in patients with advanced or metastatic non-squamous NSCLC being treated with ixabepilone and bevacizumab.
Interventions
- DRUG bevacizumab
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057212
The ClinicalTrials.gov registry entry for NCT01057212 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT01057212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057212 about?
NCT01057212 is a clinical study titled "Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)". This is a non-randomized, open-label, single arm phase II trial of the combination of bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC progressive after first or second-line therapy. The main objective is to evaluate the progression-free survival in patients wi...
What is the current status of trial NCT01057212?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2010-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01057212?
The interventions under investigation include: bevacizumab (DRUG), ixabepilone (DRUG).
Who is sponsoring clinical trial NCT01057212?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.